OncoCyte Corporation (OCX)

OncoCyte Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 25, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	98	40	21	38	200	161
Market Cap Growth	94.02%	94.02%	-45.76%	-80.98%	24.52%	37.45%
Enterprise Value	92	41	14	14	162	159
Last Close Price	3.39	2.38	2.50	6.42	43.40	47.80
PS Ratio	23.56	21.30	13.74	39.74	91.06	132.18
PB Ratio	-7.90	-3.26	0.81	0.96	3.07	4.80
P/TBV Ratio	-	-	-	-	-	17.31
EV/Sales Ratio	48.90	21.64	9.60	15.07	73.75	130.37
Debt / Equity Ratio	-0.30	-0.30	0.11	0.09	0.09	0.26
Debt / EBITDA Ratio	0.01	0.01	0.00	-	-	-
Asset Turnover	0.03	0.03	0.02	0.01	0.02	0.03
Quick Ratio	1.41	1.41	1.38	1.85	2.50	0.89
Current Ratio	1.62	1.62	1.49	2.11	2.77	1.03
Return on Equity (ROE)	-910.86%	-910.86%	-76.26%	-35.52%	-88.37%	-93.07%
Return on Assets (ROA)	-26.42%	-26.42%	-15.91%	-13.88%	-13.82%	-42.66%
Return on Capital (ROIC)	-146.37%	-146.37%	-38.88%	-31.60%	-26.30%	-51.52%
Earnings Yield	-62.84%	-151.40%	-134.52%	-191.48%	-32.03%	-18.62%
FCF Yield	-21.90%	-52.98%	-114.30%	-131.09%	-19.08%	-16.93%
Buyback Yield / Dilution	-70.84%	-70.84%	-38.10%	-24.61%	-35.80%	-27.65%

Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q